Information on the Target

Clivi, a pioneering Mexican startup established in 2021, is transforming diabetes management by leveraging technology to enhance patient care. With a mission to address the healthcare crisis resulting from diabetes, which has claimed over 140,000 lives in Mexico and imposes an annual economic burden of approximately US$33 billion, Clivi offers an innovative all-in-one approach designed to support the 21 million people affected by this condition. By creating accessible healthcare solutions, Clivi aims to improve the quality of life for diabetes patients, particularly those in underserved communities.

At the heart of Clivi’s operation is a dedicated team led by CEO Ricardo Moguel, known for his exemplary leadership skills acquired from his previous role at Doctoralia. Alongside him are COO Bruno Garza and CTO Kyle, who both bring significant expertise from their experiences in leading companies across various industries. With a team of over 50 professionals, Clivi is well-positioned to make a substantial impact in diabetes care across the region.

Industry Overview in Mexico

The healthcare industry in Mexico is currently grappling with a significant public health crisis, particularly with the rising prevalence of diabetes. The disease represents the second deadliest health issue in the country and disproportionately affects low-income and indigenous groups, highlighting glaring inequities in access to healthcare and resources. Furthermore, the economic implications of diabetes continue to strain the healthcare system, resulting in escalating out-of-pocket costs for millions of families.

Recent reports indicate that the diabetes epidemic, coupled with barriers to effective treatment, has resulted in a staggering healthcare disparity within Mexico. Many individuals lack access to essential healthcare services, often due to financial constraints or geographical limitations. As a result, healthcare providers, policymakers, and innovative startups like Clivi are urgently seeking solutions to alleviate this crisis.

Additionally, Mexico’s healthcare landscape is becoming increasingly receptive to technological innovations as a means to enhance patient care. Telehealth and mobile health applications have gained traction, particularly in the wake of the COVID-19 pandemic, providing opportunities for startups to fill critical gaps in service delivery. Clivi’s solution aligns with this emerging trend, bringing technology directly to patients through accessible platforms.

In summary, the diabetes management industry in Mexico is at a critical juncture, necessitating innovative solutions to address the burgeoning healthcare crisis. Clivi’s commitment to harnessing technology for diabetes management positions it favorably within this evolving sector.

The Rationale Behind the Deal

The decision to invest in Clivi stemmed from a thorough analysis of the need for innovative healthcare solutions in Mexico. Recognizing that diabetes is a pressing health issue affecting millions, our partnership with Clivi embodies a proactive approach to addressing one of the region's most critical healthcare challenges. Following extensive due diligence, we identified Clivi’s comprehensive approach to diabetes management as a promising solution with a strong potential for growth and impact.

Furthermore, our co-leading of Clivi's recent US$10 million seed funding round underlines our commitment to fostering companies that prioritize positive social change. In an industry where effective management can significantly improve health outcomes, investing in Clivi positions us to contribute to meaningful advancements in diabetes care while achieving favorable financial returns.

Information About the Investor

Dalus Capital, a key player in the venture capital landscape in Latin America, specializes in identifying and nurturing high-potential startups that can create significant social impact alongside financial success. With a strong track record of investing in technology-driven businesses, Dalus Capital is committed to supporting companies that address societal challenges while generating substantial economic returns.

By investing in Clivi, Dalus Capital reinforces its dedication to enhancing healthcare solutions in Latin America. The firm leverages its deep expertise in the health tech sector to create value for its portfolio companies, driving innovation and fostering growth in industries where it can make a difference.

View of Dealert

The investment in Clivi represents a significant opportunity not only for financial return but also for contributing to much-needed solutions in diabetes management. Given Clivi's impressive track record and strong leadership team, the startup is well-positioned to capture a sizable share of the growing health tech market in Mexico and beyond. The application of technology in healthcare, particularly in managing chronic conditions like diabetes, is crucial, and Clivi’s model stands out as a pioneering example of how to effectively address these issues.

Moreover, the platform’s commitment to accessibility through familiar communication channels like WhatsApp enhances its potential reach and effectiveness in delivering care. Clivi’s strong patient outcomes, demonstrated by the impressive results reported, further substantiate its ability to deliver on its promise of improved healthcare delivery and outcomes.

As we evaluate the broader context of healthcare in Mexico, the partnership between Dalus Capital and Clivi appears to be a strategic investment, with the potential for significant long-term impacts. By prioritizing both financial returns and social responsibility, this investment aligns with our mission to promote sustainable growth in Latin America's health technology sector.

In conclusion, investing in Clivi not only presents a valuable business opportunity, but it also serves as a powerful vehicle for transformative change in the fight against diabetes in Mexico. Through this partnership, we can contribute to narrowing healthcare disparities and improving the overall quality of life for countless patients.

View Original Article